Jin Rong Jie·2026-02-10 02:56Group 1 - The A-share innovative drug sector is experiencing significant fluctuations and has become a core highlight in the pharmaceutical industry, with companies like Wanbangde and Haixiang Pharmaceutical hitting the daily limit up [1] - Multiple stocks, including Xinlitai and Hansen Pharmaceutical, are rising in tandem, indicating a dual-leader effect and a broader market rally within the sector [1] - Increased market attention and net capital inflow are evident, showcasing a clear upward trend and structural opportunities within the sector [1] Group 2 - A major strategic partnership has been established between Innovent Biologics and Eli Lilly, enhancing confidence in the sector and promoting the globalization of domestic innovative drugs [2] - The industry is projected to experience strong growth, with a significant increase in the number of approved domestic innovative drugs and market size by 2025, alongside record-high overseas licensing transactions [2] - Continuous policy support is evident, with the 2025 version of the medical insurance catalog adding several innovative drugs, addressing implementation challenges and providing a supportive framework for industry development [2] Group 3 - The innovative drug research and development sector is a core beneficiary of policy, technology, and globalization benefits, with companies like Wanbangde and Xinlitai directly benefiting from the industry's growth [3] - The pharmaceutical raw materials and CDMO sectors, represented by Haixiang Pharmaceutical, are also benefiting from the commercialization of innovative drugs, leading to increased demand [3] - The traditional Chinese medicine innovative drug sector is experiencing growth due to industry innovation and policy support, with companies like Hansen Pharmaceutical and Qianjin Pharmaceutical participating in the sector's upward trend [3]